Form 4: Mirum Pharmaceuticals CEO Sells Shares
Insider Transaction (Form 4)
Christopher Peetz, CHIEF EXECUTIVE OFFICER and a Director of Mirum Pharmaceuticals, Inc., sold 20,000 shares of common stock on August 10, 2026.
Summary
- Option exercise/conversion: acquired 20,000 Common Stock at $2.94 ($58,720) on August 10, 2026; holds 214,309 after (Direct).
- Open-market sale: disposed of 11,683 Common Stock at $98.51 ($1,150,892) on August 10, 2026; holds 202,626 after (Direct).
- Open-market sale: disposed of 6,017 Common Stock at $99.25 ($597,187) on August 10, 2026; holds 196,609 after (Direct).
- Open-market sale: disposed of 2,300 Common Stock at $100.14 ($230,322) on August 10, 2026; holds 194,309 after (Direct).
- Option exercise/conversion: disposed of 20,000 Employee Stock Option (right to buy) on August 10, 2026; holds 88,487 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,978,402 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Christopher Peetz — Director, Officer (CHIEF EXECUTIVE OFFICER)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-10 | Option exercise/conversion | Common Stock | 20,000 | $3 | $58.7K | 214,309 |
| 2026-08-10 | Open-market sale | Common Stock | 11,683 | $99 | $1.2M | 202,626 |
| 2026-08-10 | Open-market sale | Common Stock | 6,017 | $99 | $597.2K | 196,609 |
| 2026-08-10 | Open-market sale | Common Stock | 2,300 | $100 | $230.3K | 194,309 |
| 2026-08-10 | Option exercise/conversion | Employee Stock Option (right to buy) | 20,000 | — | — | 88,487 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-10 | Option exercise/conversion (20,000 shares) |
| 2026-08-10 | Open-market sale (11,683 shares) |
| 2026-08-10 | Open-market sale (6,017 shares) |
| 2026-08-10 | Open-market sale (2,300 shares) |
| 2026-08-10 | Option exercise/conversion (20,000 shares) |
Keywords
insider transaction, Form 4, MIRM, Mirum Pharmaceuticals, Inc., bearish, Christopher Peetz
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.